Advancing a Potent Inhibitor of SARS-CoV-2 3CL Protease into Clinical Trials

Key facts

Disease
COVID-19
Start & end year
2020
2020
Known Financial Commitments (USD)
$678,177
Funder
Canadian Institutes of Health Research (CIHR)
Principal Investigator
D Lorne J Tyrrell
Research Location
Canada
Lead Research Institution
University of Alberta Medical Microbiology and Immunology
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
Phase 1 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase I
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

The coronavirus, SARS-CoV-2, has caused COVID-19, a disease that is currently pandemic. The drug GC376 targets an enzyme in the virus that stops its replication. This drug has been used successfully to treat a fatal disease in cats known as Feline Infectious Peritonitis (FIP). FIP is caused by a coronavirus similar to the virus causing COVID-19. This study will move GC376 into phase I human trials on the path to bringing this compound to the benefit of patients with COVID-19.